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Abstract
Steroid hormone receptors have been shown to bind to response elements in the upstream regulatory region (URR) of human
papillomavirus (HPV) in a ligand-dependent manner to affect viral promoter activity. To better understand how the enhancer activity of the
URR differs between high risk HPV types, we chose to compare the basal and glucocorticoid-dependent activities of the URRs of HPV18
and HPV31. We found that the URR of HPV18 is a stronger enhancer than the URR of HPV31 in six different cell lines of epithelial origin.
Furthermore, the activity of the URR of HPV31 was not inducible by the synthetic glucocorticoid dexamethasone (dex) in any cell line
tested, while the URR of HPV18 was dex-inducible in the majority of these lines. These studies indicate significant differences between the
URRs of high risk HPV types.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
The upstream regulatory region (URR) of the HPV ge-
nome is responsible for the transcriptional regulation of the
major early promoter, which controls expression of the early
genes of the virus (Howley, 1996). These genes are in-
volved in replication, transcription, and oncogenesis. Nu-
merous cellular as well as viral transcription factors bind to
the URR, including the viral early proteins E1 and E2
(Laimins, 1996), AP1 (Butz and Hoppe-Seyler, 1993;
Chong et al., 1990; Hubert et al., 1999; Kanaya et al., 1997;
Kyo et al., 1995), NF1 (Gloss et al., 1989), Oct-1 (Hoppe-
Seyler et al., 1991; Kyo et al., 1995), C/EBP (Baker and
Howley, 1987; Bauknecht and Shi, 1998; Grassmann et al.,
1996), Sp1 (Apt et al., 1996; Hubert et al., 1999), YY1
(Dong and Pfister, 1999; Kanaya et al., 1997), and Tef-1
(Kanaya et al., 1997).
As not all women who are infected with HPV develop
cervical cancer, it is thought that cofactors are involved.
Epidemiology indicates that users of oral contraceptives are
at an increased risk of developing cervical cancer, and that
this risk is further increased with duration of use (Brinton,
1991; Hildesheim et al., 1990; Ursin et al., 1994; WHO
Collaborative Study, 1993). Glucocorticoid response ele-
ments (GREs) have been identified in the URR of several
HPV types, including HPV11, HPV16, and HPV18 (Butz
and Hoppe-Seyler, 1993; Chan et al., 1989; Gloss et al.,
1987; Medina-Martinez et al., 1996; Mittal et al., 1993a),
and glucocorticoids have been shown to enhance the trans-
forming ability of HPV (Durst et al., 1989; Mittal et al.,
1993b; Pater et al., 1988). While these data indicate that
steroid hormones may act as cofactors to increase the risk of
developing cervical cancer, the effects of steroid hormones
on the viral life cycle have yet to be determined.
In this report we chose to compare the basal and glu-
cocorticoid-inducible activities of the URRs of HPV18 and
HPV31. The URR of HPV18 has been shown to contain a
GRE that is responsible for glucocorticoid inducibility
(Butz and Hoppe-Seyler, 1993; Medina-Martinez et al.,
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1996). It has been suggested, but never demonstrated, that
the URR of HPV31 contains at least one GRE as well
(Goldsborough et al., 1989). Therefore, we were interested
in comparing the basal and glucocorticoid-inducible activ-
ities of the URRs of these HPV types. These studies show
that the basal activity of the URR of HPV18 was higher than
that of HPV31 in all cell types tested, although the activities
were closely comparable in the HPV31-positive CIN612-9E
(9E) line. With the exception of the HPV-negative cervical
carcinoma line C33A, the HPV18 URR was inducible by
the synthetic glucocorticoid dexamethasone (dex) in all cell
types tested. On the other hand, the URR of HPV31 was
only weakly inducible in some cell lines, and not inducible
at all in others. These studies are evidence for significant
differences between the natural histories of HPV18 and
HPV31, and provide the foundation to study the steroid
hormone-inducibility of the URRs of these HPV types.
Results
Comparison of the basal activities of the URRs of HPV18
and HPV31
In order to analyze and compare the basal activities, the
URRs of HPV18 and HPV31 were cloned into the firefly
luciferase reporter plasmid pGL2-B, and transfected into a
variety of cell lines of epithelial origin (Table 1). Upon analysis
Fig. 1. Basal activities of the URR of HPV31 (31URR; white bars) and HPV18 (18URR; black bars) in six different cell lines. Relative luciferase activity
is shown as a fold change over the empty vector pGL2-B, which was set to 1. Results represent an average of three independent experiments, which were
themselves performed in duplicate. Error bars represent standard deviations.
Table 1
Description of cell lines used in this study
Cell line HPV DNA type Derivation References
CIN612-9E (9E) Episomal HPV31b CIN1 biopsy (Bedell et al., 1991)
HCK18:1Bj Episomal HPV18 Transfected primary cervical keratinocytes (Meyers et al., 1997)
HeLa Integrated HPV18 Cervical carcinoma (Chen et al., 1996; Sailaja et al., 1999;
von Knebel Doeberitz et al., 1991)
SCC13 none Squamous cell carcinoma of the cheek (Kanaya et al., 1997; Rheinwald and
Beckett, 1981)
C33A none Cervical carcinoma (Crook et al., 1991)
HaCaT none Spontaneously immortalized keratinocytes (Boukamp et al., 1988; Sailaja et al.,
1999)
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of luciferase activity, we found that the basal activity of
HPV18 URR was higher than that of HPV31 URR in all cell
lines tested (Fig. 1). These results indicate that the major early
promoter of HPV18, p105, is overall a stronger promoter than
the early promoter of HPV31, p99, in these cell lines, which
are all of squamous epithelial origin. As HPV is an epithelio-
tropic virus, this would suggest that p105 is a stronger pro-
moter than p99 in terms of the HPV life cycle in general. The
highest activity for HPV18 URR was seen in the spontane-
ously immortalized keratinocyte line, HaCaT. Interestingly,
although the basal activity of HPV18 URR is higher than
HPV31 URR in all cell lines tested, the difference between
activities in the 9E line is minimal. In addition, HPV31 URR
had its highest activity in this cell line. As the 9E cell line
maintains episomal HPV31b, a subtype of HPV31, and is
capable of producing infectious virus on raft cultures (Meyers
et al., 1992), it is possible that all factors, viral and cellular, are
present to allow for strong activity of the p99 promoter. This is
in comparison to other cell lines that either are HPV negative,
or contain a different HPV type. Conversely, the activity of
HPV18 URR is only moderate in the HCK18:1Bj line, which
maintains episomal HPV18, and is also capable of producing
infectious virus on raft cultures (Meyers et al., 1997). There-
fore, the idea that the presence of the identical HPV type stably
maintained in the cell line cannot explain the differences in
basal activities. The fact that the 9E cell line is derived from a
CINI lesion and HCK18:1Bj was created in vitro may instead
play a role in determining the basal activity of the URR.
Glucocorticoid receptor content in epithelial cell lines
Before analyzing the effect of steroid hormones on the
transcriptional activities of the HPV18 and HPV31 URRs,
we first determined whether the cell lines being used in this
study expressed the glucocorticoid receptor. Monolayer cul-
tures of 9E, HCK18:1Bj, HeLa, SCC13, C33A, and HaCaT
were analyzed by immunohistochemistry using a primary
antibody to the glucocorticoid receptor / (GR). Repre-
sentative staining is shown for monolayer cultures (Fig. 2).
All cell lines tested were positive for GR in monolayer
culture (Fig. 2, panels A–F). Immunohistochemistry using a
10 blocking peptide to the primary antibody indicated that
staining observed was specific for GR (Fig. 2, panels G–L).
Dexamethasone-inducibility of the URRs of HPV18 and
HPV31
Once we determined the presence of the glucocorticoid
receptor in all cell lines used in this study, we wanted to
analyze the effect of steroid hormones on the basal activities
of the URRs of HPV18 and HPV31. Glucocorticoids have
been shown to increase the enhancer activity of the URR of
various HPV types, and to enhance the transforming ability
of the high risk HPV type, HPV16 (Chan et al., 1989; Pater
et al., 1988). These studies suggest that glucocorticoids may
be important factors in the development of cervical cancer
due to HPV infection, and are potential therapeutic targets.
Therefore we chose to analyze the effect of the synthetic
glucocorticoid dexamethasone (dex) on the enhancer activ-
ities of the URRs of HPV18 and HPV31 in all six cell lines
described (Table 1).
Cells were seeded in Deficient media, which lacks hy-
drocortisone and phenol red, and is supplemented with
Fig. 2. Immunohistochemical analysis of monolayer cultures for the pres-
ence of glucocorticoid receptor. Cells were analyzed for the presence of the
glucocorticoid receptor (GR; Panels A–E). Panels G–L indicate staining
with 10 blocking peptide. Monolayer cultures that were analyzed include
9E (Panel A, G), HCK18:1Bj (Panel B, H), HeLa (Panel C, I), SCC13
(Panel D, J), C33A (Panel E, K) and HaCaT (Panel F, L). Arrows indicate
cells stained positive for GR.
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dextran-coated, charcoal-stripped serum to remove endog-
enous steroid hormones. Cells were then transfected with
the empty vector, pGL2-B, or the experimental constructs
pGL2-18URR and pGL2-31URR, and treated with either
vehicle (0.1% EtOH) or a titration of dex ranging from 108
M to 105 M. After assaying for luciferase activity, we
found some surprising results. As shown in Fig. 3, the
activity of the HPV31 URR was not inducible by dex in any
cell line at any concentration of dex tested, with the possible
exception of 9E, where inducibility was weak (Fig. 3, white
bars, panels A). The activity of the URR of HPV18, how-
ever, was strongly induced by dex in five of the six cell lines
tested, 9E, HCK18:1Bj, HeLa, SCC13, and HaCaT (Fig. 3,
black bars, panels A, B, C, D, and F). This induction was
concentration dependent in the 9E cell line, but appeared
saturated at the lowest concentration of dex in all other cell
lines. HPV18 URR activity was not induced in C33A cells
(Fig. 3, panel E). It is interesting to note that C33A is
positive for GR (Fig. 2, panel E), but neither URR is
inducible by dex in this cell line.
Discussion
In this report we have demonstrated that the enhancer
activity of the URR of HPV18 is stronger than that of
Fig. 3. Induction of the enhancer activities of the URR of HPV31 (31URR; white bars) and HPV18 (18URR; black bars) upon dex treatment. Cells were
transfected with either pGL2-31URR (31URR) or pGL2-18URR (18 URR) and treated with titrating amounts of dex ranging from 108 M to 105 M.
Relative luciferase activity is shown as a fold change over pGL2-31URR under vehicle conditions (veh), which was set to 1. Results represent an average
of three independent experiments, which were themselves performed in duplicate. Error bars represent standard deviations. Any effect of dex on the empty
vector pGL2-B was taken into account for all experiments.
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HPV31 in a variety of epithelial cell lines. Furthermore, we
have shown that the URR of HPV18 was inducible by dex
in the majority of cell lines tested, while the URR of HPV31
was not. These studies indicate that there are substantial
differences in enhancer activities between high risk HPV
types, and argues that early viral gene expression is different
as well. As the URR controls expression of viral genes
involved in viral replication, transcription, and oncogenesis,
it is important to understand how the URR regulates the
activity of the viral major early promoter. Additionally,
responsiveness of the URR to glucocorticoids may be a
determining factor for the association of HPV with cervical
cancer risk.
Materials and methods
Cell culture and plasmid constructs
To measure transcriptional activity of the URRs of
HPV18 and HPV31, we used HeLa, C33A, HaCaT, SCC13,
CIN612-9E, and HCK18:1Bj cell lines, presented in Table
1. HeLa and C33A cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum and gentamycin. SCC13, 9E, Ha-
CaT, and HCK18:1Bj cell lines were cultured in Epithelial
medium (E medium) with 5% FBS along with mitomycin-C
treated J2 fibroblasts as previously described (Meyers et al.,
1992). To remove endogenous steroid hormones from the
media and serum, for transfection experiments cells were
grown in E medium lacking phenol red and hydrocortisone,
and supplemented with 5% dextran-coated, charcoal-
stripped fetal bovine serum (Cocalico, Reamstown, PA).
We termed this medium Deficient medium. All cells were
maintained in a 37°C, 5% CO2 incubator. The URRs of
HPV18 and HPV31 were cloned into the promoterless,
enhancerless pGL2-Basic (pGL2-B) firefly luciferase re-
porter construct (Promega Corp., Madison, WI) as previ-
ously described (Bromberg-White and Meyers, 2002; Sen et
al., 2002).
Transfection and luciferase assay
Cells were transfected by the Large Scale Transfections
with Perfect Lipids™ Pfx-8 (Invitrogen, Carlsbad, CA) ac-
cording to manufacturer specifications and as previously
described (Sen et al., 2002). For glucocorticoid-inducible
studies, cells were treated with vehicle (0.1% EtOH) or with
a titration of 108 M of 105 M of dexamethasone (dex).
Mitomycin-C treated J2 fibroblasts were then seeded at a
density of 5 104 cells per dish. After 48 hours, cell lysates
were prepared using Passive Lysis Buffer (Promega), and
luciferase assays were performed with a Turner Designs TD
20/20 Luminometer using the Luciferase Assay System
(Promega) as recommended by the manufacturer. Lucif-
erase values were normalized so that the relative luciferase
activity is shown as a fold change over either pGL2-B (for
basal activity studies) or pGL2-31URR under vehicle con-
ditions (for dex studies).
Immunohistochemistry
In order to determine steroid hormone receptor content
of monolayer cultures, cells were grown to confluence on
Lab-Tek Flaskette glass slides (Nalge Nunc International,
Naperville, IL). Cells were washed with PBS, fixed in 10%
neutral buffered formalin, and stored at 4°C. Immunohisto-
chemical analyses were performed with the Vectastain Elite
ABC Kit (Vector Laboratories, Burlingame, CA) (Meyers et
al., 1992; Ozbun and Meyers, 1996). Primary antibody for
glucocorticoid receptor (GR) (M-20) was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). GR primary
antibody is reactive against both  and  isoforms. All
immunohistochemistry was also performed in the presence
of a 10 blocking peptide, corresponding to the primary
antibody used, to ensure that the staining observed was not
due to background levels of staining.
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